Cellular Biomedicine Group (CBMG) Releases Earnings Results, Misses Estimates By $0.01 EPS

Cellular Biomedicine Group (NASDAQ:CBMG) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.01), MarketWatch Earnings reports. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.05 million. Cellular Biomedicine Group had a negative net margin of 13,988.39% and a negative return on equity of 44.62%.

Shares of NASDAQ:CBMG traded up $0.08 on Thursday, hitting $17.09. 8,907 shares of the company were exchanged, compared to its average volume of 34,517. Cellular Biomedicine Group has a one year low of $12.04 and a one year high of $25.00. The company has a market cap of $312.98 million, a price-to-earnings ratio of -9.60 and a beta of 2.91.

Several research analysts recently commented on the stock. BidaskClub downgraded shares of Cellular Biomedicine Group from a “hold” rating to a “sell” rating in a report on Friday, October 26th. Robert W. Baird assumed coverage on shares of Cellular Biomedicine Group in a report on Wednesday, February 6th. They issued an “outperform” rating and a $26.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $27.67.

TRADEMARK VIOLATION NOTICE: “Cellular Biomedicine Group (CBMG) Releases Earnings Results, Misses Estimates By $0.01 EPS” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2019/02/21/cellular-biomedicine-group-cbmg-releases-earnings-results-misses-estimates-by-0-01-eps.html.

Cellular Biomedicine Group Company Profile

Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis.

See Also: How to Invest in an Index Fund

Earnings History for Cellular Biomedicine Group (NASDAQ:CBMG)

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit